Brief: Polaryx Therapeutics Receives U.S. FDA Fast Track Designations For All Four Indications To Be Evaluated In The Soteria Basket Trial
21/04/2026 13:48
Polaryx Therapeutics, Inc PLYX.O: POLARYX THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATIONS FOR ALL FOUR INDICATIONS TO BE EVALUATED IN THE SOTERIA BASKET TRIAL POLARYX THERAPEUTICS, INC - TO INITIATE SOTERIA PHASE 2 TRIAL IN SECOND HALF OF 2026 Source text: ID:nGNXgfyxS Further company coverage: PLYX.O
Recent news on Polaryx Therapeutics
See all newsBrief: Polaryx Therapeutics Closes $10 Million Private Placement Equity Financing
U.S. STOCKS ON THE MOVE-Northern Trust, UnitedHealth, Tractor Supply
U.S. STOCKS ON THE MOVE-Intel, Teradyne, MSCI
Polaryx rises after FDA grants fast-track status for rare disease drug
Brief: Polaryx Therapeutics Receives U.S. FDA Fast Track Designations For All Four Indications To Be Evaluated In The Soteria Basket Trial